Drug intelligence / Profile preview

EPI-N06

Development stage: Unknown
Lead developer: EpiPharm
Modality: Small Molecules
Administration: Topical

Overview

EPI-N06 is a topical therapeutic candidate developed by EpiPharm for the treatment of melanocytic pigmented lesions, including nevi (moles), age spots, and hyperpigmentation. It functions by modulating the melanin formation pathway to reduce or alter pigmentation in targeted skin areas. The drug has completed Phase 1/2 clinical testing, demonstrating its potential as a non-invasive alternative to surgical removal or laser therapy for pigmented skin lesions.

Beyond the preview

Go deeper on EPI-N06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPI-N06.

Explore the full profile